Literature DB >> 22684586

Differential effects of nerve growth factor on expression of dopamine 2 receptor subtypes in GH3 rat pituitary tumor cells.

Zhipeng Su1, Xiaolong Jiang, Chengde Wang, Jie Liu, Yunxiang Chen, Qun Li, Jinsen Wu, Weiming Zheng, Qichuan Zhuge, Kunlin Jin, Zhebao Wu.   

Abstract

Nerve growth factor (NGF) can increase expression of dopamine 2 receptors (D2R) in GH3 rat pituitary tumor cells (GH3 cells). As D2R exists in long (D2L) and short (D2S) isoforms, effects of NGF on D2R subtypes have not been accurately evaluated. In this study, we compared mRNA levels of D2R subtypes in GH3 cells treated with or without NGF with real-time RT-PCR. In addition, we also evaluated the relationship between GH3 cell growth after bromocriptine treatment and mRNA levels of D2R subtypes. We found that D2R total, D2L, and D2S mRNA in GH3 cells were significantly increased after NGF treatment, compared with the vehicle group. Moreover, NGF increased the ratio of D2S to D2L. GH3 cell survival rate after bromocriptine treatment was negatively correlated with D2R total mRNA, and D2S may be more potent than D2L in inhibiting cell growth. Cell apoptosis rate was highly elevated in GH3 cells treated with NGF and bromocriptine, compared with the control group or the group treated with NGF or bromocriptine alone. Our data provide preliminary evidence that the effect of NGF was more prominent on expression of D2S than D2L, in addition, D2S might have a greater impact suppressing GH3 cells growth than D2L.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684586     DOI: 10.1007/s12020-012-9715-y

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  20 in total

Review 1.  Medical management of prolactin-secreting pituitary adenomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

2.  Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment.

Authors:  Rosario Pivonello; Carmela Matrone; Mariagiovanna Filippella; Luigi M Cavallo; Carolina Di Somma; Paolo Cappabianca; Annamaria Colao; Lucio Annunziato; Gaetano Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

Review 3.  Medical treatment of prolactinomas.

Authors:  Annamaria Colao; Silvia Savastano
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

4.  Alternative splicing directs the expression of two D2 dopamine receptor isoforms.

Authors:  B Giros; P Sokoloff; M P Martres; J F Riou; L J Emorine; J C Schwartz
Journal:  Nature       Date:  1989 Dec 21-28       Impact factor: 49.962

5.  Polypyrimidine tract-binding protein 1 regulates the alternative splicing of dopamine receptor D2.

Authors:  Toshikazu Sasabe; Eugene Futai; Shoichi Ishiura
Journal:  J Neurochem       Date:  2010-12-02       Impact factor: 5.372

6.  Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up.

Authors:  Zhe Bao Wu; Chun Jiang Yu; Zhi Peng Su; Qi Chuan Zhuge; Jin Sen Wu; Wei Ming Zheng
Journal:  J Neurosurg       Date:  2006-01       Impact factor: 5.115

Review 7.  Recent advances in the molecular biology of dopamine receptors.

Authors:  J A Gingrich; M G Caron
Journal:  Annu Rev Neurosci       Date:  1993       Impact factor: 12.449

8.  Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.

Authors:  Christiaan de Bruin; Alberto M Pereira; Richard A Feelders; Johannes A Romijn; Ferdinand Roelfsema; Diane M Sprij-Mooij; Maarten O van Aken; Aart-Jan van der Lelij; Wouter W de Herder; Steven W J Lamberts; Leo J Hofland
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

9.  Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior.

Authors:  Zhe Bao Wu; Wei Ming Zheng; Zhi Peng Su; Yong Chen; Jin Sen Wu; Cheng De Wang; Chen Lin; Yan Jun Zeng; Qi Chuan Zhuge
Journal:  J Neurooncol       Date:  2010-01-09       Impact factor: 4.130

10.  Dopamine-induced apoptosis of lactotropes is mediated by the short isoform of D2 receptor.

Authors:  Daniela Betiana Radl; Jimena Ferraris; Valeria Boti; Adriana Seilicovich; Dipak Kumar Sarkar; Daniel Pisera
Journal:  PLoS One       Date:  2011-03-25       Impact factor: 3.240

View more
  5 in total

1.  Nerve growth factor, D2 receptor isoforms, and pituitary tumors.

Authors:  Cristina Missale
Journal:  Endocrine       Date:  2012-12       Impact factor: 3.633

2.  ACT001 inhibits pituitary tumor growth by inducing autophagic cell death via MEK4/MAPK pathway.

Authors:  Lin Cai; Ze-Rui Wu; Lei Cao; Jia-Dong Xu; Jiang-Long Lu; Cheng-de Wang; Jing-Hao Jin; Zhe-Bao Wu; Zhi-Peng Su
Journal:  Acta Pharmacol Sin       Date:  2022-01-26       Impact factor: 7.169

Review 3.  Association of craniopharyngioma and pituitary adenoma.

Authors:  Federica Guaraldi; Nunzia Prencipe; Valentina di Giacomo; Massimo Scanarini; Valentina Gasco; Marina Paola Gardiman; Alessandro M Berton; Ezio Ghigo; Silvia Grottoli
Journal:  Endocrine       Date:  2013-02-02       Impact factor: 3.633

4.  Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas.

Authors:  Zhichao Gao; Lin Cai; Jianglong Lu; Chengde Wang; Qun Li; Jian Chen; Xiaoxiao Song; Xianbin Chen; Linlin Zhang; Weiming Zheng; Zhipeng Su
Journal:  Med Sci Monit       Date:  2017-04-15

Review 5.  Dopamine Agonists for Pituitary Adenomas.

Authors:  Odelia Cooper; Yona Greenman
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-21       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.